Jiangsu Hengrui Pharmaceuticals Co.,Ltd
600276.SS
Below: live stock price for Jiangsu Hengrui Pharmaceuticals Co.,Ltd (600276.SS), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Jiangsu Hengrui Pharmaceuticals Co.,Ltd (600276.SS) is a Healthcare company based in China. Operating in Drug Manufacturers - Specialty & Generic, it employs about 20,602 people. Over the past year 600276.SS traded between 41.89 and 65.83 CNY. Trailing P/E sits near 36.16 on a market cap of about 321.64B CNY. It currently yields 0.41% in dividends.
- Prev close
- $7.29
- Volume (24h)
- $439.09M
- Market cap
- $48.22B
- Currency
- USD (native CNY)
Score
53/ 100 · Mixed
- Value46
- Quality73
- Momentum18
- Growth12
- Risk68
- Dividend53
- Liquidity100
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 7.1941 -0.99%
- +20 bars
- 7.0963 -2.33%
- +60 bars
- 7.0588 -2.85%
- +120 bars
- 7.0574 -2.87%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: 1σ ≈ ±2.17% per bar.
Interpretation
Composite signals look mixed. Strength: balance-sheet liquidity with weakness: growth. Price sits in the middle of the recent range, trend is sloping downward.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value46/100
Value looks mixed — driven by P/E (36.16).
P/E:36.16P/B:4.78PEG:0.93 - Quality73/100
Quality looks solid — driven by Gross margin (86.36%).
ROE:13.94%ROA:7.77%Profit margin:27.04%Gross margin:86.36% - Momentum18/100
Momentum looks fragile — driven by 52w change (-23.56%).
52w change:-23.56% - Growth12/100
Growth looks fragile — driven by Earnings growth (-14.60%).
Revenue growth:-14.50%Earnings growth:-14.60% - Risk68/100
Risk looks solid — driven by Debt / equity (0.11).
Beta:0.05Debt / equity:0.11 - Dividend53/100
Dividend looks mixed — driven by Payout ratio (14.93%).
Dividend yield:0.41%Payout ratio:14.93% - Liquidity100/100
Liquidity looks strong — driven by Current ratio (7.91).
Current ratio:7.91Quick ratio:7.25
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 244 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 32.8%
- Max drawdown
- -33.9%
- Below period high
- -26.4%
- Best day
- +8.75%
- Worst day
- -6.00%
- Up days
- 41%
- Current streak
- 1 down
- Typical day swing
- 2.8%
- Volume vs average
- -11%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 8.3784 high → 6.2808 low · 60 bars
- ResistanceFib +161.8% extensionnot reached11.7723 USD+62.02% from current
- ResistanceFib +100% extensionnot reached10.4759 USD+44.18% from current
- ResistanceFib +61.8% extensionnot reached9.6747 USD+33.15% from current
- ResistanceFib +27.2% extensionnot reached8.9489 USD+23.16% from current
- ResistanceFib 23.6% retracementtested 6×7.8833 USD+8.50% from current
- ResistanceFib 38.2% retracementtested 1×7.5771 USD+4.28% from current
- ResistanceFib 50% midpointNearesttested 3×7.3296 USD+0.88% from current
- Current7.2658 USD
- SupportFib 61.8% retracementtested 12×7.082 USD-2.53% from current
- SupportFib 78.6% retracementtested 7×6.7297 USD-7.38% from current
- SupportFib −27.2% extensionnot reached5.7102 USD-21.41% from current
- SupportFib −61.8% extensionnot reached4.9845 USD-31.40% from current
- SupportFib −100% extensionnot reached4.1832 USD-42.43% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- ¥65.83
- 52w low
- ¥41.89
- 52w change
- -23.56%
- Day high
- ¥49.39
- Day low
- ¥48.35
- P/E (TTM)
- 36.16
- Forward P/E
- 31.89
- PEG
- 0.93
- Price / Book
- 4.78
- Beta (5Y)
- 0.05
- Enterprise value
- 281.28B
- EV / Revenue
- 8.56
- EV / EBITDA
- 28.48
- EPS (TTM)
- ¥1.34
- Forward EPS
- ¥1.52
- Dividend yield
- 0.41%
- Dividend rate
- ¥0.20
- Payout ratio
- 14.93%
- Revenue (TTM)
- 32.85B
- EBITDA
- 9.88B
- Free cash flow
- 1.55B
- Total cash
- 38.84B
- Total debt
- 67.98M
- Debt / Equity
- 0.11
- Current ratio
- 7.91
- Quick ratio
- 7.25
- Profit margin
- 27.04%
- Gross margin
- 86.36%
- Return on assets
- 7.77%
- Return on equity
- 13.94%
- Shares outstanding
- 6.38B
- Float
- 3.73B
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
Analyst & Risk
Analysts' consensus via Yahoo Finance — not investment advice.
- Beta (vs S&P 500)
- 0.05
- very stable
- 52-week change
- -23.56%
- Debt / Equity
- 0.11
- low leverage
- Current ratio
- 7.91
- Quick ratio
- 7.25
- ROE
- 13.94%
- ROA
- 7.77%
- PEG ratio
- 0.93
- EV / Revenue
- 8.56
- EV / EBITDA
- 28.48
- Revenue growth
- -14.50%
- Earnings growth
- -14.60%
- EBITDA
- 9.88B
- Free cash flow
- 1.55B
- Total cash
- 38.84B
- Total debt
- 67.98M
- Insider holdings
- 46.55%
- Institutional
- 11.73%
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.